Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fat Injection Clear all
Completed Phase 3 Interventional Results available

The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis

NCT03467919
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Pain
Interventions
Micro Fragmented Adipose Tissue, Corticosteroid injection
Biological
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02163902
View directory record Official record
Conditions
Submental Fat, Healthy
Interventions
ATX-101, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
13
States / cities
San Diego, California • Englewood, Colorado • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
View directory record Official record
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

NCT01169103
View directory record Official record
Conditions
Obesity
Interventions
recombinant human growth hormone (rhGH), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 22, 2026, 5:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites

NCT01750424
View directory record Official record
Conditions
Scar Formation, Autologous Fat Grafting
Interventions
Autologous Fat Grafting, No intervention
Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

NCT02503852
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Puregraft System, Celution System, Kerastem Therapy, Liposuction
Device · Procedure
Lead sponsor
Kerastem Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

NCT03818737
View directory record Official record
Conditions
Osteoarthritis
Interventions
Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
40 Years to 70 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Completed No phase listed Observational

Autologous Fat Grafting Techniques in Patients Undergoing Reconstructive Surgery

NCT02677012
View directory record Official record
Conditions
Health Status Unknown
Interventions
Autologous Fat Graft, Reconstructive Surgery
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

NCT06005441
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 injection, CBL-A1 Injection, CBL-A2 Injection, 0.9% Sodium Chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 22, 2026, 5:16 AM EDT
Not listed Phase 3 Interventional

Allograft Adipose Injectable for Vocal Fold Paralysis

NCT04700566
View directory record Official record
Conditions
Vocal Fold Palsy
Interventions
Renuva Allograft Adipose Matrix
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

NCT05254418
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
dulaglutide injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01426373
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
18
States / cities
Beverly Hills, California • La Jolla, California • San Juan Capistrano, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

DailyDose Smart Snack Study for T1D on MDI

NCT05967260
View directory record Official record
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
DailyDose Smart Snack app, Dexcom G6 CGM
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Withdrawn Phase 2 Interventional

Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis

NCT05005000
View directory record Official record
Conditions
Arthritis
Interventions
Micro-Fragmented Adipose Tissue (MFAT), Triamcinolone Acetonide 10mg/mL
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01542034
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiological Evaluation of Radiesse Implantation in the Hands

NCT02949921
View directory record Official record
Conditions
Volume Loss in the Dorsum of the Hand
Interventions
Radiesse injectable implant and 2% lidocaine HCL
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

NCT06828666
View directory record Official record
Conditions
Osteoarthritis of Knee
Interventions
Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo)
Biological · Other
Lead sponsor
Britecyte
Network
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Baltimore, Maryland • Hagerstown, Maryland • Oxon Hill, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Obesity in Women Via Estradiol Regulation

NCT00687739
View directory record Official record
Conditions
Obesity
Interventions
leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)

NCT01274611
View directory record Official record
Conditions
Axillary Hyperhidrosis
Interventions
Botulinum Toxin Type A, Suction-Curettage
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 22, 2026, 5:16 AM EDT
Recruiting Not applicable Interventional

Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint

NCT03513731
View directory record Official record
Conditions
Osteoarthritis of Facet Joint of Lumbar Spine
Interventions
Adipose-derived stem cell injection, Corticosteroid injection
Device · Drug
Lead sponsor
InGeneron, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Deerfield Beach, Florida • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

NCT05760248
View directory record Official record
Conditions
Subcutaneous Fat Disorder
Interventions
10XB-101 Solution for Injection, 6.0%, Placebo Solution for Injection (no active ingredient)
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rolling Meadows, Illinois • New Brighton, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiesse® Safety Study For the Treatment of Hands

NCT02904096
View directory record Official record
Conditions
Volume Loss in the Dorsum of the Hand
Interventions
Radiesse injectable implant and 2% lidocaine HCL
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
22 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
9
States / cities
Sacramento, California • San Diego, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

NCT04126603
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebos
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
20 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 22, 2026, 5:16 AM EDT